

RECEIVED
CENTRAL FAX CENTER

APR 27 2005

PATENT

Docket No. 255.0001 0122

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Lisa K. NOLAN et al.)	Group Art Unit:	1645
)		
Serial No.:	09/738,599)	Examiner:	Sarvamanagala J. N. Devi
Confirmation No.:	1240)		
)		
Filed:	15 December 2000)		
)		
For:	NUCLEIC ACID ENCODING AN AVIAN <i>E. COLI</i> ISS POLYPEPTIDE AND METHODS OF USE			

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Since this Information Disclosure Statement is submitted after the receipt of an Office Action in the above-identified patent application, Applicants authorize a charge to Deposit Account No. 13-4895 for the fee of \$180 under 37 C.F.R. §§1.97(c) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 13-4895.

Information Disclosure Statement

Page 2 of 2

Applicant(s): Lisa K. NOLAN et al.

Serial No.: 09/738,599

Confirmation No.: 1240

Filed: 15 December 2000

For: NUCLEIC ACID ENCODING AN AVIAN *E. COLI* ISS POLYPEPTIDE AND METHODS OF USE

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to **Mail Stop Amendment**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 27th day of April, 2005, at 10:44 a.m. (Central Time).

Signature: Name: Rachel Gebhardt-Gebhardt

Respectfully submitted for

Lisa K. NOLAN et al.

By

Muetting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220

Facsimile: (612)305-1228

Customer Number 26813

Date

April 27, 2005By: 

David L. Provence

Reg. No. 43,022

Direct Dial (612)305-1005

OMB No. 0651-0011

Page 1 of 1

INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 255.00010122	Serial No.: 09/738,599
	Applicant(s): Lisa K. NOLAN et al.	Confirmation No.: 1240
	Application Filing Date: 15 December 2000	Group: 1645
	Information Disclosure Statement mailed: 27 April 2005	

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
	X	Lásaro et al., "Combined Vaccine Regimen Based on Parenteral Priming with a DNA Vaccine and Administration of an Oral Booster Consisting of Recombinant <i>Salmonella enterica</i> Serovar Typhimurium Vaccine Strain for Immunization against Infection with Human-Derived Enterotoxigenic <i>Escherichia coli</i> Strains," Infection and Immunity, 72(11):6480-6491 (Nov. 2004).
	X	Kim et al., "Protection against very virulent infectious bursal disease virus in chickens immunized with DNA vaccines," Veterinary Microbiology, 101:39-51 (2004).
	X	Verfaillie et al., "Priming of piglets against enterotoxigenic <i>E. coli</i> F4 fimbriae by immunisation with FAEG DNA," Vaccine, 22:1640-1647 (2004).

EXAMINER	Date Considered
<small>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	